|
⚲
|
| Keyboard |
| Symmetry Investments US LLC
✚
|
|
|---|---|
| CRD # | 317755 |
| SEC # | 801-128668 |
| CIK # | 0001861029, 0002004843, 0002111130, 0002055506, 0001691919 |
| AUM | 16.83 B (2026-03-31) |
| Employees | 10 (90% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-381-4000 |
| Address | 510 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Fees and Compensation
Symmetry Funds. Symmetry US receives compensation indirectly from the Symmetry Funds.
For its management services, the Delegating Manager receives compensation, including
management fees, business and technology services fees and performance fees, from the
Symmetry Funds. The Delegating Manager then compensates Symmetry US for its investment
advisory services pursuant to our sub-advisory arrangement with Symmetry Investments (Hong
Kong) Limited (“SIHKL”).
Separately Managed Accounts. Separately managed account fees are negotiated on a client-by-
client basis and are determined based upon a number of factors including, but not limited to, the
amount and type of advice provided, the size of the asset base, the complexity of the portfolio
and the resources that we anticipate dedicating to the account. Depending on the agreement with
the relevant Client, we can charge management fees that are calculated on the value of the assets
in the SMA, including assets that are financed with leverage or margin, as well as an incentive or
performance fee or allocation (which entitles us to additional compensation based on the increase
in value of those Clients’ accounts or other metrics that we agree to with those Clients). Where
we serve as a sub-adviser to an SMA, our compensation is received subject to the sub-advisory
arrangement with the master adviser (e.g., the Delegating Manager).
Timing. Management fees can be assessed against or deducted from Client accounts on a
periodic basis (e.g., monthly in arrears), but billing matters are individually negotiated and
modified under each sub-advisory arrangement.
Modification. Advisory and other fees generally may be modified in accordance with the terms
of the relevant investment management agreements.
Other Types of Fees or Expenses
Each Client bears its own expenses, including but not limited to:
• pass-through expenses including certain investment talent and acquisition costs and trade
facilitation costs;
• investment expenses (e.g., brokerage commissions, expenses relating to short sales,
clearing and settlement charges, custodial and depositary fees, bank service fees and
interest expenses);
• investment-related travel expenses;
• professional fees relating to investments;
• fees and expenses relating to software tools, programs or other technology;
• research and market data;
• administrative expenses;
• legal expenses;
• external accounting and valuation expenses;
• audit and tax preparation expenses;
• the costs of any ERISA fidelity bond;
• fees of the directors of the Client’s general partners;
• costs relating to directors’ and officers’ liability insurance;
• costs of printing and mailing reports and notices;
• taxes;
• corporate licensing;
• regulatory expenses;
• expenses related to complying with the legal, compliance, regulatory, collateral and
reporting obligations of, and preparing and making, regulatory and compliance filings
associated with the respective Client’s investment activities;
• listing fees;
• organizational expenses;
• expenses incurred in connection with the offering and sale of the interests issued by the
Symmetry Funds and other similar expenses related to the Symmetry Funds;
• indemnification expenses; and
• extraordinary expenses.
We do not accept, and none of our supervised persons accepts, compensation for the sale of
securities or other investment products.
SMA expense charges and reimbursement arrangements are reflected in the relevant investment
management agreement.
Symmetry US Revenues
As indicated above, Symmetry US acts only as a sub-adviser. As a sub-adviser, Symmetry US
does not have any direct advisory relationships with the Symmetry Funds or with the SMA.
Symmetry US receives its compensation from the Delegating Manager. The amount of
compensation that the Adviser receives is not fixed, and is based on a number of factors,
including Symmetry US’ infrastructure and other costs and expenses and the effect of the
contributions of Symmetry US’ personnel. In some cases, Symmetry US will receive some of its
compensation directly from an affiliate of the SMA client. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7: Types of Clients
Our Clients are:
• the Symmetry Funds, described in Item 4 above, which are generally open to investment
from institutional investors including, without limitation, investment managers, pension
plans, sovereign wealth and endowments, family offices, and also other sophisticated
investors which may include high net-worth individuals; and
• the SMAs, described in Item 4 above. As of the date of this Brochure, we only sub-
advise one private fund SMA. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Apple Inc | 0.0 | ||
| Nvidia Corp | 0.0 | ||
| Cisco Systems Inc | 0.0 | ||
| Amazon Com Inc | 0.0 | ||
| Tempus AI Inc | 0.0 | ||
| Tesla Motors Inc | 0.0 | ||
| Microsoft Corp | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 16.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 16.8 |
| By Discretionary | ||
| Discretionary | 3 | 16.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 16.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 16.8 | |
| United States Persons | 0.0 | |
| Total | 3 | 16.8 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001691919] | |
| 3 | [0001861029] | |
| 4 | [0001861029] | |
| 13F-HR | [0002004843] | |
| 13F-NT | [0002055506] | |
| D | [0002111130] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| LEI | 549300POXWQLZSEOUF89 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-14 | Sell | 4,699 | $34.11 | 160,283 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-14 | Sell | 1,260 | $34.11 | 42,979 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-14 | Sell | 24,726 | $34.11 | 843,404 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-14 | Sell | 7,141 | $34.11 | 243,580 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-14 | Sell | 6,593 | $34.11 | 224,887 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-11 | Sell | 3,262 | $33.80 | 110,256 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-11 | Sell | 621 | $33.80 | 20,990 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-11 | Sell | 12,237 | $33.80 | 413,611 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-11 | Sell | 3,533 | $33.80 | 119,415 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-11 | Sell | 2,324 | $33.80 | 78,551 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-10 | Sell | 2,183 | $32.68 | 71,340 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-10 | Sell | 585 | $32.68 | 19,118 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-10 | Sell | 3,063 | $32.68 | 100,099 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-10 | Sell | 3,317 | $32.68 | 108,400 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-10 | Sell | 11,485 | $32.68 | 375,330 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-09 | Sell | 4,192 | $33.64 | 141,019 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-09 | Sell | 22,070 | $33.64 | 742,435 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-09 | Sell | 6,372 | $33.64 | 214,354 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-09 | Sell | 5,883 | $33.64 | 197,904 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2021-06-09 | Sell | 1,121 | $33.64 | 37,710 |
| showing 20 of 30 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Penserra Capital Management LLC
✚
|
CA | 17.50 B |
|
Limekiln Real Estate Investment Management LP
✚
|
NY | 17.50 B |
|
Life Cycle Investment Partners Limited
✚
|
17.30 B | |
|
Bosera Asset Management International Co Limited
✚
|
17.26 B | |
|
Keystate Advisory LLC
✚
|
NV | 16.59 B |
|
Aristotle Investment Services LLC
✚
|
CA | 16.50 B |
|
Valley View Consulting LLC
✚
|
16.40 B | |
|
Venerable Investment Advisers LLC
✚
|
PA | 16.27 B |
|
Blue Owl Technology Credit Advisors LLC
✚
|
NY | 16.10 B |
|
FS/KKR Advisor LLC
✚
|
PA | 16.10 B |